Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: drug prices

Trio Wins Chemistry Nobel for Work on Antibody Drugs & Detergents

Daniel Dickson and Ben Hirschler  |  October 4, 2018

STOCKHOLM/LONDON (Reuters)—Two Americans and a Briton won the 2018 Nobel Prize for Chemistry on Wednesday for harnessing the power of evolution to generate novel proteins used in everything from environmentally friendly detergents and biofuels to cancer drugs. The fruits of this work include the world’s top-selling prescription medicine – the antibody injection Humira sold by…

Filed under:AwardsDrug UpdatesProfessional TopicsRheumatoid Arthritis Tagged with:AbbVieantibody drugs and detergentsAwardsFrances ArnoldGeorge SmithGregory WinterHumira

Oklahoma Medicaid Tests New Tactic to Curb U.S. Drug Costs

Deena Beasley  |  August 23, 2018

LOS ANGELES (Reuters)—A new front in the battle over the cost of expensive medicines in the United States is opening up in Oklahoma, the first state where the government’s Medicaid program is negotiating contracts for prescription drugs based on how well they work. In June, Oklahoma received approval from the U.S. Centers for Medicare and…

Filed under:Drug UpdatesPractice Support Tagged with:Alkermes PlcAristada (aripiprazole lauroxil)drug costsnegotiating contractsOklahoma Medicaid programPrescription drugsU.S. Centers for Medicare and Medicaid Services (CMS)

U.S. to Boost Drug Price Negotiation in Medicare Advantage Health Plans

Reuters Staff  |  August 8, 2018

(Reuters)—The Trump administration said on Tuesday it would give Medicare Advantage health plans for the elderly new tools to negotiate for lower prescription drug prices. The Centers for Medicare and Medicaid Services (CMS) said Medicare Advantage plans will be allowed to require that patients first try certain lower-cost drugs before moving to a more expensive…

Filed under:Legislation & Advocacy Tagged with:Centers for Medicare & Medicaid Services (CMS)drug price negotiationMedicare Advantage health plansTrump administration

Drug Commercials—How Are They Still a Thing?

Philip Seo, MD, MHS  |  July 19, 2018

Picture this: It’s 3 o’clock in the morning. You can’t sleep. You settle in front of the television to watch a rerun of Dirty Dancing. And then it hits you: Ask your doctor. Even as your eyelids sag, some part of your primitive forebrain snaps to attention. Medical training has turned us all into multitaskers,…

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:patient communicationpatient management

ACR Responds to Drug Pricing Proposals

Mary Beth Nierengarten  |  June 21, 2018

Responding to the Trump administration’s drug pricing proposals, the ACR released a set of principles it hopes will help guide any drug policy changes.1 The principles underscore what is critically needed for rheumatologists to provide the best and safest care to their patients, many of whom require ongoing treatment for chronic conditions. “The ACR has…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:ACR principlesAmerican Patients First Drug Pricing Blueprintdrug policy changesTrump administration’s drug pricing proposals

ACR/ARHP Visits the Hill; Drug Pricing ‘Blueprint’ Revealed

Angus Worthing  |  June 8, 2018

Greetings, Advocates! In my last update, I described the great news from February’s budget agreement that fixed Medicare’s payment adjustments so MIPS penalties would not include Part B drug costs, ensuring stabilization of the Medicare Part B drug system, among other successes. (Read the ACR’s press release on this topic.) I also described the Trump administration’s…

Filed under:American College of RheumatologyLegislation & Advocacy Tagged with:Association of Rheumatology Professionals (ARP)Biosimilarsdrug pricesfly-inWashington D.C. update

Trump Says Drug Companies to Announce “Massive” Price Cuts Soon

Reuters Staff  |  May 31, 2018

WASHINGTON (Reuters)—President Donald Trump on Wednesday said he expects major drug companies to slash prices on their products in two weeks, but did not provide details on which companies would do so or how such reductions would be made. Health care lobbyists in Washington said they were caught by surprise and had no idea what…

Filed under:Drug Updates Tagged with:drug price cutsHealth and Human Services Department (HHS)major drug companiesPresident Donald Trump

FDA Names Drugmakers Potentially Acting to Delay Cheap Generics

Michael Erman  |  May 18, 2018

(Reuters)—The U.S. Food and Drug Administration on Thursday listed drugmakers, including Celgene Corp, Johnson & Johnson, Gilead Sciences and Novartis AG, who the regulator says are potentially blocking access to samples of their drugs to delay generic competition. Generic drugmakers may not be able to develop alternatives without access to samples of branded products they…

Filed under:Professional Topics Tagged with:Celgene Corp.delay cheap genericsdelay generic competitionGilead SciencesJohnson & JohnsonNovartis AGU.S. Food and Drug Administration (FDA)

Generic-Drug Price Fixing: Is It Happening?

Philip Seo, MD, MHS  |  May 17, 2018

It started with an inhaler. Like many of you, I am a rheuma­tologist. And like you, I see some patients more often their own primary care provider. This is so often the case that I have gradually devolved into their backup, all-purpose doctor. I am the doc they notify when they get hospitalized for pneumonia…

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:generic competitiongeneric drug makersnot-for-profit generic drugmaker

ACR Leads Coalition Response to HHS Proposed Drug Pricing Threats

Carina Stanton  |  April 20, 2018

Potential federal drug pricing proposals could shuffle Part B drug coverage into the Part D program and restructure reimbursements for new drugs, moves that would jeopardize patient access to care, explains Kent “Kwas” Huston, MD, a rheumatologist in Kansas City, Mo., and a member of the ACR’s Government Affairs Committee (GAC). “We believe Part D…

Filed under:Legislation & Advocacy Tagged with:coalition responseHHSKent “Kwas” HustonPart B drug coverageproposed drug pricing threatsrestructure reimbursements

  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 25
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences